Dynamk Capital Announces New General Partner, Reinhard Vogt

Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science companies, announces today the addition of Reinhard Vogt as a new General Partner & Managing Director, effective immediately.  Reinhard joins the fund currently led by Daniella Kranjac, Founding Partner, and Mario Kranjac, Founding Partner and General Counsel.  Reinhard comes to Dynamk Capital with a wealth of industry knowledge, technology deal-side expertise and numerous technology licenses, acquisitions and integrations at one of the industry’s largest players, Sartorius AG.  What this means to investors and portfolio companies is a winning combination of commercial and operational support derived from Reinhard’s experience with more than a dozen high-profile, accretive deals throughout his time at Sartorius.   He was instrumental in building and transforming their filtration business from $30 million in the 90s, to what is now today the Sartorius Bioprocess Business of around $1.2 billion.   

Reinhard commented “Dynamk Capital stood out to me from the very start as it met an underserved market providing vital capital to life science companies making the leap from early stage to commercial success before exiting.  I am excited to work with the Dynamk team again and apply this innovative approach to broader opportunities in the market”. 

Earlier in his career Reinhard was instrumental in transforming Sartorius’ strategy to become the leader in single-use bioprocessing technologies, essentially revolutionizing how biologics are manufactured.  His track record includes technology licenses and acquisitions ranging from the Stedim SA and B. Braun Biotech transactions to more recent deals including TAP Biosystems, Cellca, BioOutsource and Umetrics.  He served as Executive VP and Member of the Board of Sartorius AG for over 10 years and as Director of several companies of the Sartorius Group. Reinhard has a unique talent and proven track record of value creation by targeting companies and technologies that when integrated create a solution aimed at speeding the development and commercialization of therapeutics.  The end result is a success story where biotech pioneers get access to the best in class technologies and technology providers realize maximum commercial value.   

Decades of navigating the competitive life sciences landscape are the basis of Dynamk’s instinctive ability to not only identify winning technologies but to strategically map out gaps they can fill in the offering of companies for exit strategies.  This combined with Dynamk’s vast network ensures portfolio companies are well positioned from the start to exit with maximum returns.     

About Dynamk Capital

Dynamk Capital LLC is a venture capital firm investing in early stage life sciences companies.  Dynamk’s investment strategy is centered on identifying companies developing disruptive technologies, tools and services that enable the full biopharma continuum across discovery, development and manufacturing of therapeutics.  The Dynamk team includes experienced life science entrepreneurs, investors, advisors and subject matter experts.  Please visit www.dynamk.vc for more information.